Ontario eConsult Service

The Ontario Rheumatology Association is working on improving patient access to specialist rheumatologic care across the province. One of the ways that this could be improved is enhanced access to subspecialist rheumatologists for […]

Read More…


Drug Shortage Update – Methotrexate

There is a drug shortage update for Methotrexate. More information is available via this link: Drug Shortage MTX […]

Read More…


Ondansetron for Methotrexate-Induced Nausea/Vomiting

The ORA EAP Committee met with the MOHLTC last year and submitted a request to have ondansetron funded for pediatric patients with rheumatic diseases who are receiving weekly oral or subcutaneous methotrexate. It […]

Read More…


Updated Notice – Temporary Facilitated Access Mechanism

Please find the attached notice from the Executive Officer regarding an update to pharmacies about the claims submission process under the Temporary Facilitated Access Mechanism (TFA Rheumatology) using the Health Network System (HNS). […]

Read More…


Health Canada and Biosimilar Drugs – Important Information for Healthcare Professionals

The following notice was received by the ORA from Health Canada on December 3, 2018: Health Canada’s Biologics and Genetic Therapies Directorate is asking healthcare professionals who prescribe, dispense or administer biologic drugs […]

Read More…


Opportunity for Arthritis Health Professionals!

Do you know ou know or work with health professionals who want to stay current withevidence-based knowledge in the field of rheumatology and arthritis care? Please share this important information: AHPA Opportunities […]

Read More…


A New Quality Standard is Now Available for Osteoarthritis

For further information, please visit this link: New Quality Standard – Osteoarthritis […]

Read More…


Concerned About the CPSO Draft Policy Titled “Continuity of Care?”

The following link will take you to the members’ only section of our website. Here you will find instructions on how to share your concerns about the CPSO draft policy. You will be […]

Read More…


New Infliximab Biosimilar (Renflexis) Approved by ODB With LU code Criteria

To review the update from the MOHLTC, please visit this link: Renflexis FAQs. The updated ORA EAP Forms are available via this link: ORA EAP Forms. […]

Read More…


OHIP+ Changes

With the recent change in provincial government leadership, many of you may be wondering how the OHIP+ Program will be affected. The ORA Executive has reached out to our key contacts at the […]

Read More…